Cadenza Bio, Inc. is a biotech startup focusing on developing novel small molecule compounds to treat Multiple Sclerosis by promoting remyelination through targeting Estrogen Receptor β (ERβ).

Deka Biosciences is a biotech company that aims to improve immunotherapy treatments by combining biology with precision medicine, specifically through their investigational new drug, DK210 (EGFR), which has dissociated IL-2 potency from toxicity.

PatchRx is a medication management startup that uses a patented smart pill bottle device and a provider web app, along with on-staff nurses, to improve patient outcomes and medication adherence, with plans to expand its technology into clinical trials and psychiatric markets.